

an Open Access Journal by MDPI

Journal of Pharmaceutical and BioTech Industry



[mdpi.com/
journal/
jpbi](https://mdpi.com/journal/jpbi)



Message from the Editor-in-Chief

Journal of Pharmaceutical and BioTech Industry (ISSN 2813-9380) is a digital, open access journal dedicated to the discovery, development, delivery, and manufacturing of pharmaceuticals and biopharmaceuticals. The journal provides a platform for the dissemination of knowledge to the pharmaceutical community, including academia, industry, and regulatory agencies as well as the general public, who will have unlimited and free access to the content as soon as a paper is published. Because of your expertise in relevant disciplines, I kindly invite you and your colleagues to consider publishing a research article or a review. Our active editorial board and dynamic editorial staff will process your manuscripts efficiently. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published online immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to process your contribution soon.

Editor-in-Chief

Prof. Dr. Ecevit Bilgili

Aims

Journal of Pharmaceutical and BioTech Industry (ISSN 2813-9380) is a peer-reviewed, open access journal dedicated to the dissemination of applied and translational research studies pertaining to the pharmaceutical and biotechnology sectors. *Journal of Pharmaceutical and BioTech Industry* aims to create a platform through which scientists and engineers from academia, industry, regulatory, and other governmental agencies share and complement each other's discoveries and advance science, engineering, and technology with the goal of enhancing patient wellbeing. All aspects of discovery, development, delivery, and manufacturing of drugs (drug substances, drug products, including biodrugs, delivery devices, diagnostic agents, etc.) are covered.

We accept original research articles, critical and timely reviews, short communications, opinions, technical notes, reports, and expert perspectives. While studies performed by a single university, laboratory, or company are expected to be the norm, collaborative studies performed by multiple constituencies, e.g., academia–industry, academia–regulator, or academia–industry–regulator, are especially welcome, as are inter- or multi-disciplinary studies. The main criteria for publication are originality, high scientific quality, and studies of interest to the pharmaceutical and biotech industry sectors. Full experimental details and/or methods of study must be provided in the submitted research articles. We ask all our authors to carefully consider and declare any potential conflicts of interests.

Scope

- Early drug discovery and development
- Product characterization and pre-clinical testing
- Drug delivery systems and drug design
- Active pharmaceutical ingredient (API) production
- Formulation, device, and packaging development
- Process development, optimization, scale-up, and manufacturing
- Pharmaceuticals and biopharmaceutics
- Mathematical modeling, simulations, and digital twins
- Pharmacokinetics, pharmacodynamics, and metabolism–transport of drugs
- Pharmaceutical nanotechnology and biotechnology
- Natural products and green chemistry
- Toxicology
- Clinical trials
- Regulatory and legislative approval
- Patent analysis.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Rapid Publication

First decisions in 16 days; acceptance to publication in 5.8 days (median values for MDPI journals in the first half of 2024)

MDPI is a member of

CASPA




STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

jpbi@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

September 2024

